MX2011008731A - Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. - Google Patents
Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.Info
- Publication number
- MX2011008731A MX2011008731A MX2011008731A MX2011008731A MX2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A MX 2011008731 A MX2011008731 A MX 2011008731A
- Authority
- MX
- Mexico
- Prior art keywords
- rtki
- eye
- delivery
- compounds
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al desarrollo de composiciones farmacéuticas eficaces en la forma de soluciones acuosas que comprenden un agente activo en una cantidad terapéuticamente efectiva y un polietilenglicol que tiene un peso molecular de al menos 2000.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15692209P | 2009-03-03 | 2009-03-03 | |
PCT/US2010/026033 WO2010101992A1 (en) | 2009-03-03 | 2010-03-03 | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008731A true MX2011008731A (es) | 2011-09-29 |
Family
ID=42678800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008731A MX2011008731A (es) | 2009-03-03 | 2010-03-03 | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20100227905A1 (es) |
EP (1) | EP2403335B1 (es) |
JP (1) | JP5583146B2 (es) |
KR (2) | KR20160135372A (es) |
CN (1) | CN102340991B (es) |
AU (1) | AU2010221369B2 (es) |
BR (1) | BRPI1012302A2 (es) |
CA (1) | CA2753690A1 (es) |
ES (1) | ES2508290T3 (es) |
MX (1) | MX2011008731A (es) |
WO (1) | WO2010101992A1 (es) |
ZA (1) | ZA201105505B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371865B1 (en) | 2006-04-07 | 2017-07-12 | Aerpio Therapeutics, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
RU2519123C2 (ru) | 2009-07-06 | 2014-06-10 | Аэрпио Терапьютикс Инк. | Соединения, композиции и способы предупреждения метастазов раковых клеток |
EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
MX2013000578A (es) * | 2010-07-21 | 2013-02-21 | Alcon Res Ltd | Composicion farmaceutica con caracteristicas de solubilidad incrementadas. |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
WO2013019640A1 (en) * | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Lensfree holographic microscopy using wetting films |
EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
EP2825206A1 (en) | 2012-03-16 | 2015-01-21 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
CA2871745C (en) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
AU2013256130B2 (en) | 2012-05-03 | 2017-12-21 | Alcon Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
EP2992021B1 (en) * | 2013-04-30 | 2020-07-22 | Intas Pharmaceuticals Limited | Novel cloning, expression & purification method for the preparation of ranibizumab |
WO2015127368A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
EA201791337A1 (ru) | 2014-12-15 | 2017-11-30 | Дзе Джонс Хопкинс Юниверсити | Составы сунитиниба и способы их применения в лечении глазных нарушений |
EP3250184A1 (en) | 2015-01-27 | 2017-12-06 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
CA3004886A1 (en) | 2015-11-12 | 2017-05-18 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
WO2018175922A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
CN114269341A (zh) | 2019-04-29 | 2022-04-01 | 视点制药公司 | 靶向施莱姆管的Tie-2激活剂 |
WO2021105792A1 (en) * | 2019-11-28 | 2021-06-03 | Caprika Srl | Rectal-use composition for the treatment of constipation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
ATE189772T1 (de) * | 1993-04-16 | 2000-03-15 | Wakamoto Pharma Co Ltd | Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis |
EP0842663A4 (en) * | 1996-05-07 | 2003-06-18 | Toray Industries | OPHTHALMIC PREPARATIONS |
EP1638941B1 (en) * | 2003-05-22 | 2010-06-02 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
CN101006988A (zh) * | 2005-09-26 | 2007-08-01 | 刘凤鸣 | 葛根素的缓释制剂 |
US20070148225A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US20070149593A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
KR20100051811A (ko) * | 2007-07-20 | 2010-05-18 | 알콘, 인코퍼레이티드 | 눈에 수용체 티로신 키나제 저해(rtki) 화합물을 전달하기 위한 약제학적 제제 |
-
2010
- 2010-03-03 EP EP10749258.9A patent/EP2403335B1/en not_active Not-in-force
- 2010-03-03 AU AU2010221369A patent/AU2010221369B2/en not_active Ceased
- 2010-03-03 JP JP2011553071A patent/JP5583146B2/ja not_active Expired - Fee Related
- 2010-03-03 WO PCT/US2010/026033 patent/WO2010101992A1/en active Application Filing
- 2010-03-03 CA CA2753690A patent/CA2753690A1/en not_active Abandoned
- 2010-03-03 BR BRPI1012302A patent/BRPI1012302A2/pt not_active IP Right Cessation
- 2010-03-03 ES ES10749258.9T patent/ES2508290T3/es active Active
- 2010-03-03 US US12/716,663 patent/US20100227905A1/en not_active Abandoned
- 2010-03-03 MX MX2011008731A patent/MX2011008731A/es active IP Right Grant
- 2010-03-03 KR KR1020167032103A patent/KR20160135372A/ko active IP Right Grant
- 2010-03-03 CN CN201080010150.0A patent/CN102340991B/zh not_active Expired - Fee Related
- 2010-03-03 KR KR1020117023001A patent/KR20110130454A/ko active Application Filing
-
2011
- 2011-07-26 ZA ZA2011/05505A patent/ZA201105505B/en unknown
-
2013
- 2013-01-25 US US13/749,887 patent/US20130137741A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102340991B (zh) | 2014-02-26 |
WO2010101992A1 (en) | 2010-09-10 |
EP2403335A1 (en) | 2012-01-11 |
KR20110130454A (ko) | 2011-12-05 |
US20100227905A1 (en) | 2010-09-09 |
AU2010221369B2 (en) | 2014-03-13 |
CA2753690A1 (en) | 2010-09-10 |
BRPI1012302A2 (pt) | 2015-09-22 |
JP5583146B2 (ja) | 2014-09-03 |
JP2012519694A (ja) | 2012-08-30 |
AU2010221369A1 (en) | 2011-08-25 |
EP2403335B1 (en) | 2014-08-20 |
ZA201105505B (en) | 2013-10-30 |
ES2508290T3 (es) | 2014-10-16 |
EP2403335A4 (en) | 2012-08-29 |
CN102340991A (zh) | 2012-02-01 |
US20130137741A1 (en) | 2013-05-30 |
KR20160135372A (ko) | 2016-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011008731A (es) | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. | |
TW200733958A (en) | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye | |
MX2021012934A (es) | Lipidos de amina ionizables y nanoparticulas lipidicas. | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
MX2011008680A (es) | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. | |
JO3078B1 (ar) | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة | |
MX2010010127A (es) | 1,2,4-triazoles trisustituidos como moduladores de receptores de acetilcolina nicotinicos. | |
PH12019501937A1 (en) | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | |
JO3019B1 (ar) | ثلاثي مستبدل 4،2،1-ثلاثي زولات | |
TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
WO2007076448A3 (en) | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye | |
PL2081547T3 (pl) | Postać galenowa do podawania składników czynnych poprzez śluzówkę | |
WO2012075081A3 (en) | High-strength testosterone undecanoate compositions | |
WO2007048219A3 (en) | Sustained drug release composition | |
MX2009010170A (es) | Formulaciones topicas que tienen biodisponibilidad aumentada. | |
MX2009003246A (es) | Análogos de ghrelina sustituidos en el terminal n. | |
AR075028A1 (es) | Composicion farmaceutica solida que comprende amlodipina y losartan | |
WO2012054500A3 (en) | Compositions for drug administration | |
TW200733959A (en) | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye | |
IN2013MN02384A (es) | ||
MX2010005013A (es) | Composiciones intranasales. | |
WO2012053009A3 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
RS20110136A1 (en) | PREPARATIONS CONTAINING AMLODIPINE AND BIZOPROLOL | |
WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |